65,437 trials
Anaplastic Astrocytoma · Anaplastic Oligodendroglioma · Mixed Glioma
Primary: Number of Phase I Participants With Dose-Limiting Toxicity Events (Phase I) Maximum Tolerated Dose (MTD) (Phase I) as Measured by the Number of Participants With Dose…
Rheumatoid Arthritis · Ankylosing Spondylitis · Psoriatic Arthritis
Primary: Measurement of Effector T Helper Type 17 Cells in Peripheral Blood — 466.4; 432; 450; 759.8 spSFC/10^6 — p=0.003
Skin Laxity
Primary: General Skin Appearance of Mons Pubis and Labia — 3; 4; 1 Participants
Asherman Syndrome
Primary: the AFS Score at Second-look Hysteroscopy — 6.5; 8 Units on a scale — p=<0.05
Cutaneous Melanoma
Primary: Response Rate (RECIST1.1) of Calcium Electroporation and Bleomycin Based Electrochemotherapy on Cutaneous Metastases at Day 180. — 4; 6; 2; 2 cutaneous metastases — p=0.30
Healthy
Primary: Percentage of Subjects With Drug-related Adverse Events (AEs) — 0.0; 0.0; 0.0; 0.0 Percentage of subjects
Diabetes Mellitus, Type 2 · Metabolic Syndrome · Insulin Resistance
Primary: Change From Baseline in Body Mass Index (BMI) Through Month 12 — 37.0; 37.8; -.7; -.3 kg/m^2 — p=0.04
Chronic Idiopathic Constipation
Primary: Number of Participants With Adverse Events — 3; 6; 2; 6 Participants
Constipation
Primary: The Proportion of Subjects Having a Rescue-free Bowel Movement (RFBM) Within 4 Hours After the First Injection. — 79.2; 4.3 percentage of participants — p=<0.0001
Suicidal Ideation · Emotions
Primary: Feasibility as Assessed by Attendance at Sessions for Duration of Intervention (Percent of Sessions Attended) — 66.4 percentage of sessions attended
Hypoactive Sexual Desire Disorder
Primary: Arterial Compliance - Augmentation Index — 1.067 percentage of Arterial stiffness
Metastatic Melanoma · Mucosal Melanoma · Stage IV Cutaneous Melanoma AJCC v6 and v7
Primary: Progression-free Survival (PFS) — 139; 94 days
Parkinson Disease · Anxiety
Primary: The Number of Participants Who Fail to Complete the 12-week Study on Study Drug. — 7; 0 Participants
Abuse Liability of Staccato Alprazolam
Primary: Response to EDQ Question Number 5, "Rate the Degree to Which You Would Like to Take the Drug Again" — 0; 1.714; 2.143; 2.286 units on a scale
Chronic Kidney Diseases
Primary: Number of Participants With Procedural Success — 19 Participants